Search Results | Blood | American Society of Hematology

1-20 of 49

2 3

Sort by

Sort Order Select

Journal Articles

RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment

Timothy T. Ferng, Theodore C. Tarver, III, Shaheen Kabir, Benjamin Braun, Aaron C. Logan, Luke A. Gilbert, Catherine C. Smith

Blood (2021) 138 (Supplement 1): 2236.

DOI: https://doi.org/10.1182/blood-2021-145835

Published: 2021

Journal Articles

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Blood (2021) 138 (Supplement 1): 554.

DOI: https://doi.org/10.1182/blood-2021-153074

Published: 2021

Journal Articles

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Blood (2021) 138 (Supplement 1): 2922.

DOI: https://doi.org/10.1182/blood-2021-154151

Published: 2021

Journal Articles

Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States

Juliana E. Hidalgo-Lopez, Gail J. Roboz, Brent Wood, Michael Borowitz, Elias J. Jabbour, Kelly Velasco, Ehab Elkhouly, Babatunde Adedokun, Faraz Zaman, Karim Iskander, Aaron C. Logan

Blood (2021) 138 (Supplement 1): 4478.

DOI: https://doi.org/10.1182/blood-2021-144353

Published: 2021

Journal Articles

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Blood (2021) 138 (1): 11–22.

DOI: https://doi.org/10.1182/blood.2020009098

Published: 2021

Includes: Supplemental data

Journal Articles

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Kelly L. Schoenbeck, MD, Sirisha Tummala, MD, Rebecca L. Olin, MD, Neha G. Goyal, PhD, Anand Dhruva, MD, Lloyd E. Damon, MD, Aaron C. Logan, MDPhDMPhil, Catherine C. Smith, MD, Neil P. Shah, MDPhD

Blood (2020) 136 (Supplement 1): 41–42.

DOI: https://doi.org/10.1182/blood-2020-143303

Published: 2020

Journal Articles

Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

Vanessa E Kennedy, MD, Gavin Hui, MD, Daria Gaut, MD, Varun Mittal, MD, Caspian Oliai, MD, Lori S. Muffly, MD MS, Aaron C. Logan, MDPhDMPhil, Gabriel N. Mannis, MD

Blood (2020) 136 (Supplement 1): 32–33.

DOI: https://doi.org/10.1182/blood-2020-143002

Published: 2020

Journal Articles

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

Rajni Agarwal, MD, Christopher C. Dvorak, MD, Hye-Sook Kwon, PhD, Janel R Long-Boyle, PharmD, PhD, Susan S Prohaska, PhD MS, Janice W Brown, MD, Anne Le, Alyssa Guttman-Klein, Irving L Weissman, MD, Morton J Cowan, MD, Aaron C. Logan, MD PhD, Kenneth I. Weinberg, MD, Robertson Parkman, MD, Maria-Grazia Roncarolo, MD, Judith A Shizuru, MD PhD

Blood (2019) 134 (Supplement_1): 800.

DOI: https://doi.org/10.1182/blood-2019-126239

Published: 2019

Journal Articles

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Kelly L. Schoenbeck, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Andrew D. Leavitt, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Rebecca L. Olin, MD, Giselle Salmasi, MD, Peter H. Sayre, MD PhD, Neil P. Shah, MD PhD, Anand Dhruva, MD, Chloe E. Atreya, MD PhD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 5859.

DOI: https://doi.org/10.1182/blood-2019-129638

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

DOI: https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Varun Mittal, MD, Mimi Lo, PharmD, Lloyd E. Damon, MD, Karin L. Gaensler, MD, Thomas G. Martin, III, MD, Rebecca L. Olin, MD, Catherine C. Smith, MD, Aaron C. Logan, MD PhD

Blood (2019) 134 (Supplement_1): 5089.

DOI: https://doi.org/10.1182/blood-2019-129514

Published: 2019

Journal Articles

Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice

Hye-Sook Kwon, Aaron C. Logan, Akanksha Chhabra, Wendy W. Pang, Agnieszka Czechowicz, Keri Tate, Alan Le, Jessica Poyser, Roger Hollis, Benjamin V. Kelly, Donald B. Kohn, Irving L. Weissman, Susan S. Prohaska, Judith A. Shizuru

Blood (2019) 133 (19): 2104–2108.

DOI: https://doi.org/10.1182/blood-2018-06-853879

Published: 2019

Includes: Supplemental data

Journal Articles

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice

Wendy W. Pang, Agnieszka Czechowicz, Aaron C. Logan, Rashmi Bhardwaj, Jessica Poyser, Christopher Y. Park, Irving L. Weissman, Judith A. Shizuru

Blood (2019) 133 (19): 2069–2078.

DOI: https://doi.org/10.1182/blood-2018-06-858159

Published: 2019

Includes: Supplemental data

Journal Articles

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 897.

DOI: https://doi.org/10.1182/blood-2018-99-111531

Published: 2018

Journal Articles

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A. Jonas, MD PhD, Peter T. Curtin, MD, Gary J. Schiller, MD, Deepa Jeyakumar, MD, Matthew J. Wieduwilt, MD PhD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Helen Chow, MD, Leslie G. Oesterich, MD, Aaron C. Logan, MD PhD

Blood (2018) 132 (Supplement 1): 3088.

DOI: https://doi.org/10.1182/blood-2018-99-119237

Published: 2018

Journal Articles

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

Li-Wen Huang, MD, Chiung-Yu Huang, PhD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Gabriel N. Mannis, MD, Catherine C. Smith, MD, Karin M. Gaensler, MD, Thomas G. Martin, III, MD, Lloyd E. Damon, MD, Michael A. Steinman, MD, Rebecca L. Olin, MD

Blood (2018) 132 (Supplement 1): 3599.

DOI: https://doi.org/10.1182/blood-2018-99-112025

Published: 2018

Journal Articles

A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401

Matthew J. Wieduwilt, MD PhD, Brian A. Jonas, MD, Gary J. Schiller, MD, Lin Liu, PhD, Carolyn Mulroney, MD, Gabriel N. Mannis, MD, Dimitrios Tzachanis, MD PhD, Januario E. Castro, MD, Edward D Ball, MD, Peter T. Curtin, MD, Charalambos Andreadis, MD, Aaron C. Logan, MD PhD, Jesika Reiner, MPH, Lloyd E. Damon, MD

Blood (2018) 132 (Supplement 1): 4018.

DOI: https://doi.org/10.1182/blood-2018-99-117469

Published: 2018

Journal Articles

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Brian A Jonas, MD PhD, Aaron C. Logan, MDPhDMPhil, Deepa Jeyakumar, MD, Mehrdad Abedi, MD, Rafael Bejar, MD PhD, Matthew J. Wieduwilt, Leslie G. Oesterich, MD, Peter T. Curtin, MD

Blood (2017) 130 (Supplement 1): 2973.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2973.2973

Published: 2017

Journal Articles

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

Gabriel N. Mannis, MD, Nicole Therrien, Jessica Van Ziffle, Nicole Foley, Iwei Yeh, Shan Zhong, PhD, Jie He, PhD, Michelle Nahas, PhD, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Rebecca L. Olin, MD MS, Sonam Prakash, MD, Tariq I Mughal, MD FRCP, Aaron C. Logan, MDPhDMPhil, Thomas G. Martin, III, MD

Blood (2017) 130 (Supplement 1): 1423.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1423.1423

Published: 2017

Journal Articles

The Discover Trial: Application of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Allogeneic Stem-Cell Transplant Patients

Monica Fung, MD, Hon Seng, BS, Desiree Hollemon, MSN, MPH, David Hong, MD, Timothy Blauwkamp, PhD, Mickey Kertesz, PhD, Jamie Eng, BS, Kathy Wong, BS, Aaron C. Logan, MDPhDMPhil, Peter Chin-Hong, MD

Blood (2017) 130 (Supplement 1): 1937.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1937.1937

Published: 2017

2 3

NARROW

RNA Polymerase II Is a Therapeutic Target to Overcome FLT3 Inhibitor Resistance Mediated By the Bone Marrow Microenvironment

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Non-Relapse Mortality in TP53 -Mutated MDS/AML - a Multi-Center Collaborative Study

Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Excellent Outcomes Achieved with Medical Management of Chronic Phase CML Patients with Non-Hematologic TKI Intolerance

Hypomethylating Agents in Combination with Venetoclax As a Bridge to Allogeneic Transplant in Acute Myeloid Leukemia

Non-Genotoxic Anti-CD117 Antibody Conditioning Results in Successful Hematopoietic Stem Cell Engraftment in Patients with Severe Combined Immunodeficiency

Symptom Assessment in Patients with BCR-ABL-Negative Myeloproliferative Neoplasms at an Academic Medical Institution

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

Anti-human CD117 antibody-mediated bone marrow niche clearance in nonhuman primates and humanized NSG mice

Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice

Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

A Phase 1 Trial of Ibrutinib (IBR) and Azacitidine (AZA) for the Treatment of Higher-Risk Myelodysplastic Syndromes (HR-MDS): Updated Results of University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies

A Phase 1 Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes: University of California Hematologic Malignancies Consortium (UCHMC) Study 1503

The Role of Comprehensive Mutational Profiling in Predicting Patients Who May Benefit from Autologous Hematopoietic Cell Transplant for Acute Myeloid Leukemia

The Discover Trial: Application of the Karius Plasma Next-Generation Sequencing Test for Pathogen Detection in Allogeneic Stem-Cell Transplant Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only